For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | |
|---|---|---|---|---|
| Total revenue | - | 0* | 0 | |
| General and administrative | 1,612,267 | 1,413,606* | 1,443,827 | |
| Research and development | 2,123,725 | 2,590,724* | 2,729,891 | |
| Collaboration credits | 1,233,224 | 2,091,493* | 1,658,248 | |
| In-process r&d impairment | - | 4,624,000* | 0 | |
| Change in fair value of contingent consideration | 7,427 | 3,910,925* | -1,721,033 | |
| Total operating expenses | 2,510,195 | 10,447,762* | 794,437 | |
| Operating loss | -2,510,195 | -10,447,762* | -794,437 | |
| Impairment of intangible assets | - | 0* | - | |
| Loss on disposal of fixed assets | - | 0* | - | |
| Interest income | - | 273,566* | - | |
| Interest expense | - | 4,990* | - | |
| Interest income, net | 139,338 | - | 201,822 | |
| Other expense, net | -47,127 | -89,148* | -23,708 | |
| Total other income, net | 92,212 | 179,428* | 178,114 | |
| Loss before income tax provision | -2,417,984 | -10,268,334* | -616,323 | |
| Income tax provision | 0 | 647,238* | -643,129 | |
| Net loss | -2,417,984 | -10,915,572 | 26,806 | |
| Net loss attributable to common shareholders | -2,417,984 | - | 26,806 | |
| Net loss attributable to common shareholders | -2,417,984 | -10,915,572 | 26,806 | |
| Basic EPS | -0.58 | -2.7 | 0.01 | |
| Diluted EPS | -0.58 | -2.838 | 0.01 | |
| Basic Average Shares | 4,174,802 | 4,043,531 | 4,289,853 | |
| Diluted Average Shares | 4,174,802 | 3,846,006 | 4,361,740 | |
KIORA PHARMACEUTICALS INC (KPRX)
KIORA PHARMACEUTICALS INC (KPRX)